Encube Ethicals Secures SEBI Approval for ₹3,000 Crore IPO, Paving the Way for Major Public Offering.

The Encube Ethicals IPO has successfully received approval from SEBI, allowing the company to initiate a ₹3,000 crore issue through an entirely offer-for-sale (OFS) structure. This means that the funds raised in the IPO will not benefit the company directly but will instead flow to the existing shareholders, specifically Mehul Madhusudan Shah and Frontier Investment Holdings, which is managed by Quadria Capital. This IPO is part of a sequence of approvals granted by SEBI, which also includes several other companies that filed their draft papers around the same period.

According to reports, Encube Ethicals has shown impressive growth, with a 75% increase in net profit, reaching ₹436.7 crore, alongside a 34.7% rise in revenue to ₹1,848.7 crore, compared to the previous fiscal year. However, specifics regarding the price band and valuation of the IPO have yet to be disclosed. Given that this IPO is purely an OFS, investor sentiment may focus more on the performance of existing shareholders rather than the immediate financial benefits to the company itself. As of now, grey market sentiments have not been directly mentioned, which hints at a cautious approach by investors as they await further clarifications.

This IPO presents an intriguing opportunity for Indian investors, particularly those interested in the pharmaceutical sector, which continues to show robust growth. With the approval from SEBI valid for the next 12 months, Encube is on track to file its red herring prospectus (RHP) soon, detailing the price band and other crucial information. Retail investors should consider the implications of an OFS structure, focusing on the company’s underlying growth metrics and the potential for shareholder returns over time.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova IPO team.)